| 151 |
22369694 | Impact of genetic polymorphisms on tacrolimus pharmacokinetics and the clinical outcome of renal transplantation. | 2012 Apr |
1 |
| 152 |
22476221 | Hepatitis C virus treatment and liver transplantation in the era of new antiviral therapies. | 2012 Jun |
1 |
| 153 |
22491658 | Risk of tacrolimus toxicity in CYP3A5 nonexpressors treated with intravenous nicardipine after kidney transplantation. | 2012 Apr 27 |
1 |
| 154 |
22576324 | Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers. | 2012 Nov |
1 |
| 155 |
22871995 | In vivo CYP3A4 activity, CYP3A5 genotype, and hematocrit predict tacrolimus dose requirements and clearance in renal transplant patients. | 2012 Sep |
6 |
| 156 |
22993851 | [Effect of CYP3A4*18B, CYP3A5*3 gene polymorphism on dosage and concentration of tacrolimus in renal transplant patients]. | 2012 Jul |
2 |
| 157 |
23580932 | Formulation strategies for drug delivery of tacrolimus: An overview. | 2012 Oct |
1 |
| 158 |
21635144 | Impact of the CYP3A4*1G polymorphism and its combination with CYP3A5 genotypes on tacrolimus pharmacokinetics in renal transplant patients. | 2011 Jul |
9 |
| 159 |
21753749 | In vivo CYP3A activity is significantly lower in cyclosporine-treated as compared with tacrolimus-treated renal allograft recipients. | 2011 Sep |
3 |
| 160 |
21844990 | Tacrolimus and 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors: An interaction study in CYP3A5 non-expressors, renal transplant recipients. | 2011 Jul |
1 |
| 161 |
21902502 | Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors' dose requirements and trough blood levels in stable renal transplant patients. | 2011 Oct |
2 |
| 162 |
21903774 | A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. | 2011 Nov |
1 |
| 163 |
21916909 | Association of ABCB1, CYP3A4*18B and CYP3A5*3 genotypes with the pharmacokinetics of tacrolimus in healthy Chinese subjects: a population pharmacokinetic analysis. | 2011 Oct |
1 |
| 164 |
21980965 | Successful tacrolimus treatment following renal transplant in a HIV-infected patient with raltegravir previously treated with a protease inhibitor based regimen. | 2011 |
1 |
| 165 |
22016125 | [Drug interactions and immunosuppression in organ transplant recipients]. | 2011 Oct 18 |
1 |
| 166 |
20091056 | Tacrolimus nephrotoxicity: beware of the association of diarrhea, drug interaction and pharmacogenetics. | 2010 May |
1 |
| 167 |
20097278 | Mechanistic understanding of the different effects of Wuzhi Tablet (Schisandra sphenanthera extract) on the absorption and first-pass intestinal and hepatic metabolism of Tacrolimus (FK506). | 2010 Apr 15 |
2 |
| 168 |
20305320 | Toxic tacrolimus blood levels with rifampin administration in a renal transplant recipient. | 2010 Jan-Mar |
1 |
| 169 |
20718999 | Probable tacrolimus toxicity from tibolone co-administration in a woman: a case report. | 2010 Aug 19 |
1 |
| 170 |
20832577 | Micafungin does not influence the concentration of tacrolimus in patients after allogeneic hematopoietic stem cell transplantation. | 2010 Sep |
1 |
| 171 |
20876828 | Ranolazine-tacrolimus interaction. | 2010 Nov |
1 |
| 172 |
21047202 | Using genetic and clinical factors to predict tacrolimus dose in renal transplant recipients. | 2010 Oct |
2 |
| 173 |
21104927 | Determination of a quantitative relationship between hepatic CYP3A5*1/*3 and CYP3A4 expression for use in the prediction of metabolic clearance in virtual populations. | 2010 Nov |
2 |
| 174 |
19183931 | [Drug-drug interactions in urology]. | 2009 Mar |
1 |
| 175 |
19289993 | The effect of CYP3A5 and ABCB1 single nucleotide polymorphisms on tacrolimus dose requirements in Caucasian liver transplant patients. | 2009 Jan-Mar |
1 |
| 176 |
19376366 | Genetic polymorphisms in CYP3A5 and MDR1 genes and their correlations with plasma levels of tacrolimus and cyclosporine in renal transplant recipients. | 2009 Apr |
1 |
| 177 |
19384171 | Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea. | 2009 Apr 27 |
6 |
| 178 |
19667964 | Pharmacogenetics of calcineurin inhibitors in renal transplantation. | 2009 Aug 15 |
1 |
| 179 |
19709321 | Effect of coadministered HIV-protease inhibitors on tacrolimus and sirolimus blood concentrations in a kidney transplant recipient. | 2009 Aug |
2 |
| 180 |
19728747 | Immunotherapy in elderly transplant recipients: a guide to clinically significant drug interactions. | 2009 |
1 |
| 181 |
19813492 | Tacrolimus: review of pharmacokinetics, pharmacodynamics, and pharmacogenetics to facilitate practitioners' understanding and offer strategies for educating patients and promoting adherence. | 2009 Sep |
3 |
| 182 |
18493655 | Bifunctional molecules evade cytochrome P(450) metabolism by forming protective complexes with FK506-binding protein. | 2008 Jun |
1 |
| 183 |
18556719 | Effect of aprepitant on intravenous tacrolimus disposition in reduced intensity hematopoietic stem cell transplantation. | 2008 Sep |
1 |
| 184 |
18704002 | Effects of CYP3A5 and MDR1 single nucleotide polymorphisms on drug interactions between tacrolimus and fluconazole in renal allograft recipients. | 2008 Oct |
1 |
| 185 |
18721002 | Cinacalcet does not affect the activity of cytochrome P450 3A enzymes, a metabolic pathway for common immunosuppressive agents : a randomized, open-label, crossover, single-centre study in healthy volunteers. | 2008 |
1 |
| 186 |
19005401 | Haplotypic structure of ABCB1/MDR1 gene modifies the risk of the acute allograft rejection in renal transplant recipients. | 2008 Nov 15 |
1 |
| 187 |
17202802 | Effect of cyclosporine and tacrolimus on cytochrome p450 activities in human liver microsomes. | 2007 Jan |
1 |
| 188 |
17374625 | Does metronidazole interact with CYP3A substrates by inhibiting their metabolism through this metabolic pathway? Or should other mechanisms be considered? | 2007 Apr |
1 |
| 189 |
17495880 | CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients. | 2007 Dec |
7 |
| 190 |
17889118 | Pharmacogenetics of tacrolimus and sirolimus in renal transplant patients: from retrospective analyses to prospective studies. | 2007 Sep |
2 |
| 191 |
17979656 | Maximal inhibition of intestinal first-pass metabolism as a pragmatic indicator of intestinal contribution to the drug-drug interactions for CYP3A4 cleared drugs. | 2007 Oct |
1 |
| 192 |
18159131 | Distinct effects of omeprazole and rabeprazole on the tacrolimus blood concentration in a kidney transplant recipient. | 2007 Dec |
1 |
| 193 |
16421475 | Influence of CYP3A5 gene polymorphisms of donor rather than recipient to tacrolimus individual dose requirement in liver transplantation. | 2006 Jan 15 |
1 |
| 194 |
16424824 | Effect of intestinal CYP3A5 on postoperative tacrolimus trough levels in living-donor liver transplant recipients. | 2006 Feb |
1 |
| 195 |
16753004 | Influence of different allelic variants of the CYP3A and ABCB1 genes on the tacrolimus pharmacokinetic profile of Chinese renal transplant recipients. | 2006 Jun |
3 |
| 196 |
16759707 | An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients. | 2006 Oct |
1 |
| 197 |
16906020 | Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients. | 2006 Sep |
4 |
| 198 |
16911928 | Genetic factors for individual administration of immunosuppressants in organ transplantation. | 2006 Aug |
1 |
| 199 |
15698457 | Impact of gastric acid suppressants on cytochrome P450 3A4 and P-glycoprotein: consequences for FK506 assimilation. | 2005 Mar |
3 |
| 200 |
15919446 | Initial dosage adjustment for oral administration of tacrolimus using the intestinal MDR1 level in living-donor liver transplant recipients. | 2005 May |
1 |